Popular Articles

Blogs Comment On Health Care Reform Legislation, Congressional Funding For D.C., Other Topics
The following summarizes selected women"s health-related blog entries.~ "Just the Facts, Sir: The False Dichotomy of Catholics vs. "Pro-Choice" on Common Ground," Jodi Jacobson, RH Reality Check: In anticipation of the release of the White House"s "common ground" proposal to reduce the need for abortion and help prevent unintended pregnancies, "numerous members of the male pontificator commentariat are trying to spark anxiety by claiming Obama will have to make a choice between "the Catholic vote" and "the pro-choice community,"" Jacobson writes. However, "[n]othing could be further from the truth," she states, noting that Obama received the majority of the Catholic vote in the election and that a "majority of Catholic voters approve of [his] performance to date." There is "no danger" of Obama losing Catholic support "on this particular issue, as long as the administration makes clear its values and principles and goals and objectives, and as long as it sticks to the facts," Jacobson continues. She lists several steps that the White House should take with its proposal, including making it clear that the administration is "committed to evidence-based policies in public health" and that "the best way to reduce unintended pregnancies, and hence the need for abortion, is to provide universal access to prevention services." By focusing on evidence-based public health policies, the Obama administration "can, in the long run, actually bring profound change to this debate," Jacobson writes. She concludes that "evidence-based policies put into practice will achieve many of the goals we seek and take the air out of the ideological fight in which we have been engaged" (Jacobson, RH Reality Check, 7/2).~ "Is Denying Women Abortions the Price of Bipartisanship?" Igor Volsky, Think Progress" "The Wonk Room": Volsky writes that Sen. Orrin Hatch (R-Utah) and Republican colleagues on the Senate Finance Committee reportedly are pushing health care reform legislation that would require insurers participating in a new national health insurance exchange to exclude coverage for abortion services. According to Volsky, the committee"s version of the bill would be the only piece of health care reform legislation "that specifically prohibits -- takes away, rations, if you will -- a medical service." Meanwhile, health care reform legislation being considered by the Senate Health, Education, Labor and Pensions Committee and the House"s three committees that govern health care "leaves the coverage decisions -- the design of the so-called essential benefit packages" -- to the HHS secretary or an expert committee. Volsky notes that approximately one in three U.S. women will have an abortion by age 45 and that private insurers usually cover the procedure. He writes, "As Republicans often argue, Congress should leave benefits decisions to the medical professionals." He adds that "if denying abortion services to women is the price of bipartisanship, then perhaps winning those one or two Republican votes isn"t worth the price of jeopardizing women"s health and well-being" (Volsky, "The Wonk Room," Think Progress, 7/6).~ "House Moves To Lift Bans On Abortion Funding, Needle Exchange, Domestic Partnership and Medical Marijuana in D.C.," Choice Words: The fiscal year 2010 appropriations bill currently under review in the House "would lift a number of reproductive justice-related funding bans" in the District of Columbia, including a ban on using locally-raised funds for abortion, the blog entry states. "Access to abortion in D.C. has been severely limited by anti-choice Congresspeople playing politics with the district," the blog says, noting that Congress has "supreme authority" over the district"s funding. The bill also would end bans on using funds for certain other purposes, such as domestic partnership registration and benefits, according to the blog. The blog concludes that the "fight to lift these funding bans is just beginning" and is an "important first step towards protecting reproductiv
generic viagra online
A Compound Found In The Sea Provides Promising New Treatment For Neuropathic Pain
A paper just published in the British Journal of Pharmacology reports that a compound originally isolated from a soft coral (Capnella imbricate) could lead scientists to develop a new variety of treatments for neuropathic pain. This composite is collected at Green Island off Taiwan and could be a new option for treatment. Neuropathic pain is chronic and occasionally follows damage to the nervous system. Presently this type of pain is very poorly controlled by the usual analgesics: aspirin like drugs (NSAIDS) or even opioids like morphine. New treatments are urgently required.
News of the day
Patients With Bipolar Disorder At Increased Risk For Wide Range Of Health Problems, Thomson Reuters Study Finds
A new study from Thomson Reuters found that patients with bipolar disorder were at greater risk for a wide range of medical conditions than a control group of patients with no mental health diagnoses.
Endocrinology

GlaxoSmithKline Pledges $97M Investment In AIDS Drugs For Africa, Allows South African Drugmaker To Produce Generic Second-Line Treatment

GlaxoSmithKline (GSK) on Tuesday announced plans to invest $97 million over 10 years "to improve research, development and access to AIDS drugs in Africa," Reuters reports. GSK also put forth "a new free voluntary licensing agreement for AIDS drug abacavir, or Ziagen with South African generic drugmaker Aspen Pharmacare." According to Reuters, Aspen will be able to "manufacture a cheaper generic version of the drug." GSK"s "latest stepsò€¦follow pressure from campaigners and some governments for drug companies to do more to get life-saving medicines to the poor, particularly in sub-Saharan Africa," Reuters writes. "Glaxo took a lead in February by promising to place many of its patents on drugs for tropical diseases into a free "pool," but it stopped short of offering patents on medicines for HIV/AIDS, which it does not consider to be a neglected disease" (Hirschler, 7/14). "The plans follow GSK"s historic deal in April with rival Pfizer to create a new HIV and AIDS company with 11 products," the Telegraph reports. The announcement is an "indication of the commitment that the new company will bring to fighting HIV/AIDS in the world"s poorest countries," GSK"s chief executive Andrew Witty said during a trip to Kenya (Ruddick, 7/14). Abacavir is "a "second line" antiretroviral therapy used when patients fail to respond to" standard treatment, the Financial Times reports. "The new pledges for the first time expand the waiver on rights to abacavir, and [Witty] stressed they also applied to supplies to low-income countries outside Africa provided the generic manufacturers could meet the criteria of "quality, capacity and sustainability"," the Financial Times writes. The newspaper reports that Witty does not support a patent pool for HIV drugs, and "[h]e said GSK had "a good track record" of making its medicines affordable in [middle income] countries through discounts" (Jack, 7/15). "While welcoming the initiatives, [British members of Parliament] and campaigners said GSK, and other pharmaceutical companies, must do more," the Guardian reports. "David Borrow, who chairs the all-party parliamentary group on AIDS, said: "GSK is taking positive steps, but they are broadly unilateral, which will limit their impact."ò€¦"The most effective way to reduce prices would be a patent pool approach, rather than individual deals between companies." A report released by Borrow"s group, titled, "The Treatment Timebomb," estimates that by 2030 more than 50 million people will need HIV treatment compared to just 9 million today (Kollewe, 7/14). Barrow said in a separate Guardian article, "We must reduce the price of second-line medicines and less toxic first-line medicines before millions need them. We cannot sleepwalk into a situation where we can only afford to treat a tiny proportion of those infected" (Boseley, 7/12). GSK"s pledge of $97 million will be put toward non-governmental organizations that work to prevent mother-to-child transmission of HIV and public-private partnerships for the development of pediatric HIV/AIDS drugs (GSK release, 7/14). This information was reprinted from globalhealth.kff.org with kind permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily Global Health Policy Report, search the archives and sign up for email delivery at globalhealth.kff.org. © Henry J. Kaiser Family Foundation. All rights reserved.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):